Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer - Takeaways - MDSpire
Clinical Guidelines
Feature

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

  • By

  • Julia Cipriano

  • May 5, 2026

  • 15 min

Share

  • 1

    BRCAAway trial analysis reports median overall survival of 68 months with combined therapy.

  • 2

    Key population included patients with BRCA1/2 and ATM mutations.

  • 3

    Combination therapy improved survival over monotherapies.

  • 4

    Minimal adverse events observed, confirming tolerability.

  • 5

    Results support genomic testing for personalized treatment plans.

Original Source(s)

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

  • by Julia Cipriano

  • May 5, 2026

Related Content

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies

  • May 6, 2026

  • 1 min
Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...